Pulmonary fibrosis occurs in a variety of clinical settings, constitutes a major cause of
morbidity and mortality, and represents an enormous unmet medical need. However, the …

Pulmonary fibrosis, particularly idiopathic pulmonary fibrosis, represents a chronic and
progressive disease with high mortality and limited therapeutic options. Excessive …

Fibrosis is the concluding pathological outcome and major cause of morbidity and mortality
in a number of common chronic inflammatory, immune-mediated and metabolic diseases …

Idiopathic pulmonary fibrosis (IPF) is an insidious inflammatory fibroproliferative disease
whose cause and course before diagnosis are unknown, and for which existing treatments …

Idiopathic pulmonary fibrosis (IPF) is a unique type of chronic fibrosing lung disease of
unknown etiology. The sequence of the pathogenic mechanisms is unknown, but the …

Pulmonary fibrosis is a highly heterogeneous and lethal pathological process with limited
therapeutic options. Although research on the pathogenesis of pulmonary fibrosis has …

Pulmonary fibrosis is characterized by lung inflammation and abnormal tissue repair,
resulting in the replacement of normal functional tissue with an abnormal accumulation of …

Idiopathic pulmonary fibrosis (IPF) is the most frequent fibrotic diffuse parenchymal lung
disease. Its prognosis is devastating:> 50% of the patients die within 3 years after diagnosis …

This is a time of substantial progress in the evaluation and care of patients with idiopathic
pulmonary fibrosis (IPF). In addition to the approval and widespread availability of the first …

Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible fibrosing lung disease of
unknown etiology and with an unfavorable outcome, leading ultimately to death due to …